Catalyst Diagnostic LLC

Catalyst Diagnostic LLC was paid $1.67M by Medicaid between Nov 2020 and May 2024, across 53 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 53% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Michigan

Rank by total paid#30 of 108

Median peer was paid$588K

This provider vs. median2.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	1,065	$70K
2021	20,476	$734K
2022	15,096	$597K
2023	5,660	$180K
2024incomplete	2,039	$84K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	53%	14,120	12,308	$889K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	13%	10,925	9,641	$217K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	6.6%	6,173	5,083	$110K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	4.6%	357	352	$77K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	4.4%	1,326	1,227	$73K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	2.7%	599	331	$44K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	2.4%	1,141	665	$40K
87481		2.2%	464	455	$36K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.3%	395	322	$21K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.1%	888	871	$18K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.0%	921	903	$17K
87529		<1%	364	361	$15K

41 more codes

87653		<1%	782	$14K
87632		<1%	86	$13K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	766	$13K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	468	$9K
87500		<1%	628	$9K
87641		<1%	536	$9K
87563		<1%	422	$8K
87486		<1%	291	$5K
87640		<1%	502	$4K
87541		<1%	294	$4K
87581		<1%	291	$4K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	79	$3K
87631		<1%	29	$3K
87511		<1%	136	$2K
81514		<1%	27	$1K
87483		<1%	147	$1K
87625		<1%	26	$507.23
87496		<1%	153	$373.09
87498		<1%	128	$319.45
87561		<1%	25	$172.57
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	16	$164.56
87505		<1%	31	$96.22
87551		<1%	12	$36.18
80373		0%	52	$0.00
80362		0%	37	$0.00
80337		0%	37	$0.00
80361		0%	36	$0.00
80356		0%	52	$0.00
80348		0%	52	$0.00
80346		0%	52	$0.00
80372		0%	52	$0.00
80354		0%	52	$0.00
80360		0%	36	$0.00
80365		0%	36	$0.00
80369		0%	52	$0.00
80359		0%	52	$0.00
80349		0%	52	$0.00
80353		0%	13	$0.00
80324		0%	52	$0.00
80358		0%	52	$0.00
80345		0%	21	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKIMINAIA, NORMAN (OWNER)